Descripción de la empresa
Arbutus Biopharma Corporation operates as a clinical-stage biopharmaceutical entity dedicated to the development of novel therapeutics targeting infectious diseases within the United States market, with a specific focus on its chronic Hepatitis B virus product pipeline. The company functions within the healthcare sector, specifically the biotechnology industry, which characterizes its business model as reliant on extensive research and development rather than immediate commercial sales of established products. Its current operational scale is defined by a market capitalization of $871.83M, an annual revenue of $14.08M, and a workforce comprising 19 employees. These valuation and revenue figures indicate that the company exists in a pre-revenue or early-revenue stage typical of clinical-stage biotechs, where the market capitalization reflects the potential value of its pipeline assets rather than current profitability. The disparity between its substantial market cap and its modest revenue of $14.08M highlights the market's pricing of future potential over present-day cash generation, a common dynamic for firms with significant unproven product candidates like Imdusiran.
Salud financiera
The financial performance of Arbutus Biopharma Corporation over the trailing twelve months (TTM) shows a revenue of $14.08M contrasted against a net income of -$33,501,000, revealing a cost structure where expenses significantly outpace income generation. The company reports an EBITDA of -$26,688,000, further illustrating that operational cash flows are heavily consumed by research expenditures and development costs typical of the biotechnology sector. Free cash flow stands at -$17,619,500, indicating that the company is burning cash to fund its clinical trials and operational needs, which limits immediate financial flexibility but is necessary for advancing its therapeutic candidates. The gross margin is listed at -79.2%, while the operating margin is -727.3% and the profit margin is -237.9%; these deeply negative figures reflect the high cost of drug development relative to current sales, which is standard for clinical-stage entities before a product reaches commercialization. Despite these negative margins, the company holds $91.47M in cash against only $4.19M in debt, resulting in a debt-to-equity ratio of 5.47 which suggests a leveraged balance sheet in terms of the ratio calculation but one supported by a strong cash buffer. The current ratio of 15.73 indicates an extremely strong short-term liquidity position, providing ample coverage for current liabilities and ensuring the company can meet its immediate obligations without distress. Return on Equity is -38.5% and Return on Assets is -14.9%, metrics that reveal management is currently allocating capital toward long-term asset accumulation and pipeline development rather than generating immediate returns for shareholders.
Evaluación de valoración
Valuation metrics for Arbutus Biopharma Corporation present a complex picture due to its lack of consistent profitability, with a trailing P/E ratio of N/A and a forward P/E of -26.98, implying that the market is not pricing the stock based on current earnings but on anticipated future earnings once the drug reaches commercialization. The price-to-book ratio stands at 11.21, indicating a significant market premium over the company's book value, which suggests investors are valuing the intangible assets of the pipeline and potential future royalties far above the tangible net worth recorded on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 61.91 and an EV/EBITDA of -29.40 further emphasize that the stock is priced on sales potential and speculative growth rather than cash flow or earnings power. The stock's trading range over the past year spans a 52-week high of $5.10 and a 52-week low of $2.71, meaning the current price sits somewhere within this range, reflecting the volatility inherent in clinical-stage biotechnology equities. With a beta of 0.74, the stock exhibits lower price volatility relative to the broader market, suggesting that while it may not move as sharply as the overall index, it still carries significant risk given its negative earnings and high multiple valuations.
Growth & Income
Revenue growth year-over-year is recorded at -33.2%, while earnings growth is listed as N/A due to the absence of positive earnings history; this dynamic implies that the company is currently shrinking its revenue base as it transitions from early-stage development to later clinical phases or manages its cash reserves. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available capital is theoretically reinvested into growth initiatives such as clinical trials and regulatory filings rather than distributed to shareholders. The absence of a dividend yield and a payout ratio of 0.0% confirms that the company prioritizes capital expenditure on its product pipeline over income distribution, a strategy essential for biotechnology firms in the clinical stage. Overall, the growth and income profile of Arbutus Biopharma Corporation is characterized by negative revenue growth, zero dividend distribution, and a reliance on existing cash reserves to fuel future potential rather than current profitability.